Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global NK Cells Market by Type (Mogamulizumab, Lorvotuzumab Mertansine, Others), By Application (Cancer, Cardiovascular Diseases, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global NK Cells Market by Type (Mogamulizumab, Lorvotuzumab Mertansine, Others), By Application (Cancer, Cardiovascular Diseases, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 137813 3300 Pharma & Healthcare 377 250 Pages 4.6 (47)

Market Overview:

The global NK cells market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer and cardiovascular diseases, and the growing demand for targeted therapies. The global NK cells market is segmented on the basis of type, application, and region. On the basis of type, it is divided into mogamulizumab, lorvotuzumab mertansine, and others. Mogamulizumab held a dominant share in 2017 owing to its high efficacy in treating various types of cancer such as leukemia, lymphoma, myeloma etc. On the basis of application, it is segmented into cancer therapy (solid tumors & hematological malignancies), cardiovascular diseases therapy (ischemic heart disease & stroke), and others (autoimmune disorders & transplant rejection). Cancer therapy dominated this market in 2017 due to rising incidences of different types if cancers across globe.

Global NK Cells Industry Outlook

Product Definition:

NK Cells are a type of white blood cell that helps the body fight infection and disease. They are important because they can identify and destroy cells that have been infected or damaged, which helps keep the body healthy.


Mogamulizumab (GAM-1) is a humanized monoclonal antibody designed for the treatment of patients affected by multiple myeloma and lymphomas. The drug has completed phase II clinical trials with positive outcome and is expected to be launched in near future.

NK cells are one of the most important blood cell types involved in immune surveillance against tumor metastasis, infected organisms, autoimmune diseases as well as foreign particles.

Lorvotuzumab Mertansine:

Lorvotuzumab mertansine is a humanized monoclonal antibody that targets the CD16 receptor. Lorvotuzumab mertansine has been shown to inhibit NK cell-mediated cytotoxicity in vitro and in vivo. The drug has completed phase 2 clinical trial and is currently under phase 3 clinical trial for evaluating its safety and efficacy as a treatment for Non-Ketotic Hyperglycemic Type 1 Diabetes (NKH1D).

Application Insights:

The cancer segment dominated the market in 2017 and is expected to witness lucrative growth over the forecast period. This can be attributed to increasing incidence of various types of cancers, such as lung, breast, colorectal and liver cancer. For instance, according to data published by WHO in 2018 regarding global cancer prevalence rates; around 1 in 6 women and 1 in 5 men are estimated to develop some form of cancer during their lifetime.

NK cells have been proven effective against various types of cancers including lung adenocarcinoma (ADC), non-small cell lung carcinoma (NSCLC), pancreatic ductal adenocarcinoma (PDAC) liver metastasis recurrence skin metastasis prostate tumor bone metastasis brain tumor gastrointestinal stromal tumor head & neck squamous cell carcinoma kidney tumors ureter tumors breast carcinomas hormone refractory Metastatic Breast Cancer (MBC).

Regional Analysis:

North America dominated the global market in 2017. This can be attributed to the presence of a large number of global players, high adoption rate for new therapies, and increasing incidence of cancer and cardiovascular diseases. Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising incidences of cancer and other chronic diseases coupled with growing awareness about available treatment options. Moreover, an increase in per capita income levels will boost demand further due to its cost-effectiveness compared with western medicines. The Asia Pacific held more than 40% share in 2017 as NK cells are found at higher levels among Asian population as compared to white race people from North America or Europe (1).

The U.S., China, Japan dominate clinical trials for novel immunotherapies globally; however emerging countries such as India are catching up fast due to increased focus on drug development by Indian government (2).

Growth Factors:

  • Increasing incidence of cancer and other diseases requiring immunotherapy
  • Growing demand for adoptive cell therapy
  • Rising public awareness about the benefits of NK cells-based therapies
  • Technological advancements in isolation and characterization of NK cells
  • increasing investment in research and development

Scope Of The Report

Report Attributes

Report Details

Report Title

NK Cells Market Research Report

By Type

Mogamulizumab, Lorvotuzumab Mertansine, Others

By Application

Cancer, Cardiovascular Diseases, Others

By Companies

Chipscreen Biosciences (China), Affimed NV (Netherlands), Altor BioScience Corporation (USA), Innate Pharma SA (France), Takeda Pharmaceutical (Japan), Sorrento Therapeutics Inc. (USA), NantKwest Inc. (USA), Bristol-Myers Squibb (USA), NKT Therapeutics (USA)

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global NK Cells Market Report Segments:

The global NK Cells market is segmented on the basis of:


Mogamulizumab, Lorvotuzumab Mertansine, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Cancer, Cardiovascular Diseases, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Chipscreen Biosciences (China)
  2. Affimed NV (Netherlands)
  3. Altor BioScience Corporation (USA)
  4. Innate Pharma SA (France)
  5. Takeda Pharmaceutical (Japan)
  6. Sorrento Therapeutics Inc. (USA)
  7. NantKwest Inc. (USA)
  8. Bristol-Myers Squibb (USA)
  9. NKT Therapeutics (USA)

Global NK Cells Market Overview

Highlights of The NK Cells Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Mogamulizumab
    2. Lorvotuzumab Mertansine
    3. Others
  1. By Application:

    1. Cancer
    2. Cardiovascular Diseases
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the NK Cells Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global NK Cells Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

NK cells are a type of white blood cell that helps the body fight infection. They work to destroy viruses, bacteria, and other harmful substances.

Some of the key players operating in the nk cells market are Chipscreen Biosciences (China), Affimed NV (Netherlands), Altor BioScience Corporation (USA), Innate Pharma SA (France), Takeda Pharmaceutical (Japan), Sorrento Therapeutics Inc. (USA), NantKwest Inc. (USA), Bristol-Myers Squibb (USA), NKT Therapeutics (USA).

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. NK Cells Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. NK Cells Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. NK Cells Market - Supply Chain
   4.5. Global NK Cells Market Forecast
      4.5.1. NK Cells Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. NK Cells Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. NK Cells Market Absolute $ Opportunity

5. Global NK Cells Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. NK Cells Market Size and Volume Forecast by Type
      5.3.1. Mogamulizumab
      5.3.2. Lorvotuzumab Mertansine
      5.3.3. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global NK Cells Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. NK Cells Market Size and Volume Forecast by Application
      6.3.1. Cancer
      6.3.2. Cardiovascular Diseases
      6.3.3. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global NK Cells Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. NK Cells Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global NK Cells Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. NK Cells Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global NK Cells Demand Share Forecast, 2019-2029

9. North America NK Cells Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America NK Cells Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America NK Cells Market Size and Volume Forecast by Application
      9.4.1. Cancer
      9.4.2. Cardiovascular Diseases
      9.4.3. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America NK Cells Market Size and Volume Forecast by Type
      9.7.1. Mogamulizumab
      9.7.2. Lorvotuzumab Mertansine
      9.7.3. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America NK Cells Demand Share Forecast, 2019-2029

10. Latin America NK Cells Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America NK Cells Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America NK Cells Market Size and Volume Forecast by Application
      10.4.1. Cancer
      10.4.2. Cardiovascular Diseases
      10.4.3. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America NK Cells Market Size and Volume Forecast by Type
      10.7.1. Mogamulizumab
      10.7.2. Lorvotuzumab Mertansine
      10.7.3. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America NK Cells Demand Share Forecast, 2019-2029

11. Europe NK Cells Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe NK Cells Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe NK Cells Market Size and Volume Forecast by Application
      11.4.1. Cancer
      11.4.2. Cardiovascular Diseases
      11.4.3. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe NK Cells Market Size and Volume Forecast by Type
      11.7.1. Mogamulizumab
      11.7.2. Lorvotuzumab Mertansine
      11.7.3. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe NK Cells Demand Share, 2019-2029

12. Asia Pacific NK Cells Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific NK Cells Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific NK Cells Market Size and Volume Forecast by Application
      12.4.1. Cancer
      12.4.2. Cardiovascular Diseases
      12.4.3. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific NK Cells Market Size and Volume Forecast by Type
      12.7.1. Mogamulizumab
      12.7.2. Lorvotuzumab Mertansine
      12.7.3. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific NK Cells Demand Share, 2019-2029

13. Middle East & Africa NK Cells Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa NK Cells Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa NK Cells Market Size and Volume Forecast by Application
      13.4.1. Cancer
      13.4.2. Cardiovascular Diseases
      13.4.3. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa NK Cells Market Size and Volume Forecast by Type
      13.7.1. Mogamulizumab
      13.7.2. Lorvotuzumab Mertansine
      13.7.3. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa NK Cells Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global NK Cells Market: Market Share Analysis
   14.2. NK Cells Distributors and Customers
   14.3. NK Cells Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Chipscreen Biosciences (China) Overview Financials Developments Strategic Outlook
      14.4.2. Affimed NV (Netherlands) Overview Financials Developments Strategic Outlook
      14.4.3. Altor BioScience Corporation (USA) Overview Financials Developments Strategic Outlook
      14.4.4. Innate Pharma SA (France) Overview Financials Developments Strategic Outlook
      14.4.5. Takeda Pharmaceutical (Japan) Overview Financials Developments Strategic Outlook
      14.4.6. Sorrento Therapeutics Inc. (USA) Overview Financials Developments Strategic Outlook
      14.4.7. NantKwest Inc. (USA) Overview Financials Developments Strategic Outlook
      14.4.8. Bristol-Myers Squibb (USA) Overview Financials Developments Strategic Outlook
      14.4.9. NKT Therapeutics (USA) Overview Financials Developments Strategic Outlook
      14.4.10. COMPANY 10 Overview Financials Developments Strategic Outlook
      14.4.11. COMPANY 11 Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us